This issue of Clinical Chemistry contains 3 reports from the IFCC Working Group for Standardization of Thyroid Function Tests. The first report relates to thyroidstimulating hormone (TSH) 2 (1 ), the second addresses free thyroxine (FT 4 ) and free triiodothyronine (FT 3 ) (2 ) , and the third discusses total thyroxine (T 4 ) and total triiodothyronine (T 3 ) (3 ). Each of these reports is authored by a group of experts who relate not only their own experience but also the experience of various professional organizations. This broad representation is important for the potential harmonization role that the authors hope to promote with these reports.
The chair of this group, Linda Thienpont, was also project leader for the measurements of the total and free thyroid hormones in the prior groundwork project initiated by the European Commission, "Feasibility Studies for the Development of Reference Measurement Systems for Thyrotropin (TSH) and for Free Thyroxine (FT 4 Many analytes, such as TSH, are not well defined, and reference procedures are not available. TSH is a glycoprotein that has multiple forms in blood. Donadio and colleagues have shown that circulating TSH molecules have various glycosylation patterns that may differ with different thyroid disease states (6 ) . Differences in the relative concentrations of these circulating forms and differences in immunoreactivity with the various reagent antibodies make TSH standardization very difficult. The use of targeted glycosylated forms of TSH as assay calibrators might help with the standardization, but assay differences probably would continue to exist. Further analyses of the circulating forms of TSH and their relationships to thyroid diseases may help target the preferred protein fragments and/or protein forms for use in standard reference procedures. Lopez and colleagues recently published mass spectrometric data regarding the circulating forms of parathyroid hormone and showed how they related to immunoassay reactivity (7 ) . Similar analyses of TSH may help in the development of reference methods for TSH.
Even when reference standards are not available, major steps toward harmonization can be achieved via intramethod comparisons, such as those provided in the TSH part of this series (1 ). Weighted Deming regression analyses that compare the mean of 6 replicates of the measurements for each sample contained in the panel to the overall mean for all assays is an effective way to identify the offsets for each assay. These offsets then could be used, at least theoretically, to "correct" each assay to the "consensus" mean.
Normalization factors will harmonize only the systematic differences among the assays. That is, if the regression slope is different from 1.0, the results could be factored to generate a slope of 1.0; however, if individual samples show different offsets compared with the overall regression slopes, global factors will not harmonize these results. Analyses of the data cross-plots, CVs, and correlation coefficients often help to identify the discordant subgroups.
The standardization of the smaller molecules, such as T 4 and T 3 , should be easier because these molecules are well defined and reference methods exist. It is disappointing that two-thirds of the T 3 assays had a systematic bias of Ͼ10%. Although the performance of the T 4 assays was considerably better, many T 4 assays had a systematic bias close to 10%, and 4 of 11 assays had a bias Ͼ10%. It is unclear why such large deviations continue when well-defined reference methods are available. Might this discordance be caused by differences in the protocols used by various manufacturers for value assignment of their calibrators? If there are substantial differences in the value-assignment protocols, it would be interesting to better understand whether these differences are intentional (based on financial and/or logistical factors) or are driven by an arbitrary lack of consensus.
Standardization of FT 4 and FT 3 assays represent intermediate challenges, which should be easier than for TSH but more difficult than for the total hormones. The primary reference methods for measurement of the free hormones are the same as for the total hormones. The concentrations are lower, however, and robust consensus-driven methods must be established to separate the free hormones from the bound hormones. As expected, the data for the free hormones in this series showed greater discordance between methods than the data for the total-hormone methods.
Strong cooperation between professional societies and commercial in vitro diagnostics companies will be required to achieve harmonization of these assays. This harmonization process should be facilitated by the wide representation included in this working group.
The authors of these publications have coded their test results to blind readers to the relationships of the test results to any particular manufacturer. Why the manufacturers would want to have their identity blinded is understandable, but in this era of full disclosure, public disclosure of these relationships would be helpful. This information could help clinicians better understand differences in patient care and potentially could be used to develop strategies to correct these differences. Publication of this information also may help increase the peer pressure of laboratorians to encourage commercial companies to improve their assay calibrations. On the other hand, laboratory scientists might use this information to select assays that have better standardization, which undoubtedly is a concern that companies would have about the disclosure of such information. Might publication of these assay differences, however, lead to further improvement in the harmonization of patient test results over time?
